Your browser doesn't support javascript.
loading
Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.
Sequist, Lecia V; Gray, Jhanelle Elaine; Harb, Wael A; Lopez-Chavez, Ariel; Doebele, Robert C; Modiano, Manuel R; Jackman, David Michael; Baggstrom, Maria Quintos; Atmaca, Akin; Felip, Enriqueta; Provencio, Mariano; Cobo, Manuel; Adiwijaya, Bambang; Kuesters, Geoffrey; Kamoun, Walid S; Andreas, Karen; Pipas, J Marc; Santillana, Sergio; Cho, Byoung Chul; Park, Keunchil; Shepherd, Frances A.
Afiliación
  • Sequist LV; Massachusetts General Hospital, Boston, Massachusetts, USA LVSEQUIST@PARTNERS.ORG.
  • Gray JE; H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
  • Harb WA; Horizon Oncology Center, Lafayette, Indiana, USA.
  • Lopez-Chavez A; Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA.
  • Doebele RC; University of Colorado Cancer Center, Aurora, Colorado, USA.
  • Modiano MR; Arizona Clinical Research Center, Tucson, Arizona, USA.
  • Jackman DM; Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Baggstrom MQ; Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Atmaca A; Department of Hematology and Oncology, Institute of Clinical Research at Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt, Germany.
  • Felip E; Vall d'Hebron University Hospital, Barcelona, Spain.
  • Provencio M; Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
  • Cobo M; Hospital Regional Universitario Málaga, Instituto de Investigación Biomédica de Málaga, Málaga, Spain.
  • Adiwijaya B; Merrimack Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.
  • Kuesters G; Merrimack Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.
  • Kamoun WS; Merrimack Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.
  • Andreas K; Merrimack Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.
  • Pipas JM; Merrimack Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.
  • Santillana S; Merrimack Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.
  • Cho BC; Yonsei University College of Medicine, Seoul, South Korea.
  • Park K; Department of Medicine, Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Shepherd FA; Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.
Oncologist ; 24(8): 1095-1102, 2019 08.
Article en En | MEDLINE | ID: mdl-30975923
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor / Carcinoma de Pulmón de Células no Pequeñas / Neurregulina-1 / Anticuerpos Monoclonales Humanizados / Clorhidrato de Erlotinib / Neoplasias Pulmonares Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Oncologist Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor / Carcinoma de Pulmón de Células no Pequeñas / Neurregulina-1 / Anticuerpos Monoclonales Humanizados / Clorhidrato de Erlotinib / Neoplasias Pulmonares Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Oncologist Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article